Table 1.
Selected prostate cancer trials for disease detection and radiotherapy treatment of metastatic disease.
| CTID | Abbreviated titles | Purpose | Phase | Compound | Patients | Status |
|---|---|---|---|---|---|---|
| NCT02981368 | 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY) | Diagnostic | II/III | [18F]-DCFPyL | 385 | Completed |
| NCT03739684 | 18F-DCFPyL PET/CT imaging in patients with suspected recurrence of prostate cancer (CONDOR) | Diagnostic | III | [18F]-DCFPyL | 200 | Active |
| NCT03392428 | 177Lu-PSMA617 theranostic Vs. cabazitaxel in progressive metastatic CRPC (TheraP) | Therapy | III | [177Lu]-PSMA-617 | 201 | Active |
| NCT03511664 | 177Lu-PSMA-617 in metastatic castrate-resistant prostate cancer (VISION) | Therapy | III | [177Lu]-PSMA-617 | 750 | Active |
| NCT03276572 | 225Ac–J591 in patients with mCRPC | Therapy | Ib | [225Ac]-J591 | 42 | Recruiting |
| NCT03939689 | I-131-1095 radiotherapy in combination with enzalutamide in patients with mCRPC (ARROW) | Therapy | II | [131I]-MIP-1095 | 175 | Recruiting |
| NCT02552394 | Radioimmunotheraspy in prostate cancer using 177Lu-J5912 antibody | Therapy | I | [177Lu]-J591 | 54 | Recruiting |